Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 2/2017

01-08-2017

Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination

Authors: R. Pannell, S. Li, V. Gurewich

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2017

Login to get access

Abstract

Thrombolysis with tissue plasminogen activator (tPA) has been a disappointment and has now been replaced by an endovascular procedure whenever possible. Nevertheless, thrombolysis remains the only means by which circulation in a thrombosed artery can be restored rapidly. In contrast to tPA monotherapy, endogenous fibrinolysis uses both tPA and urokinase plasminogen activator (uPA), whose native form is a proenzyme, prouPA. This combination is remarkably effective as evidenced by the fibrin degradation product, d-dimer, which is invariably present in plasma. The two activators have complementary mechanisms of plasminogen activation and are synergistic in combination. Since tPA initiates fibrinolysis when released from the vessel wall and prouPA is in the blood, they induce fibrinolysis sequentially. It was postulated that this may be more effective and fibrin-specific. The hypothesis was tested in a model of clot lysis in plasma in which a clot was first exposed to tPA for 5 min, washed and incubated with prouPA. Lysis was compared with that of clots incubated with both activators simultaneously. The sequential combination was almost twice as effective and caused less fibrinogenolysis than the simultaneous combination (p < 0.0001) despite having significantly less tPA, as a result of the wash. A mechanism is described by which this phenomenon can be explained. The findings are believed to have significant therapeutic implications.
Literature
1.
go back to reference Voskuilen M, Vermond A, Veeneman GH, van Boom JH, Klasen EA, Zegers ND, Nieuwenhuizen W (1987) Fibrinogen lysine residue Aα157 plays a crucial role in the fibrin-induced acceleration of plasminogen activation, catalyzed by tissue-type plasminogen activator. J Biol Chem 262(13):5944–5946PubMed Voskuilen M, Vermond A, Veeneman GH, van Boom JH, Klasen EA, Zegers ND, Nieuwenhuizen W (1987) Fibrinogen lysine residue Aα157 plays a crucial role in the fibrin-induced acceleration of plasminogen activation, catalyzed by tissue-type plasminogen activator. J Biol Chem 262(13):5944–5946PubMed
2.
go back to reference Hoylaerts M, Rijken DC, Lijnen HR, Collen D (1982) Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 257:2912–2919PubMed Hoylaerts M, Rijken DC, Lijnen HR, Collen D (1982) Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 257:2912–2919PubMed
3.
go back to reference Liu J, Gurewich V (1992) Fragment E-2 from fibrin substantially enhances pro-urokinase-induced glu-plasminogen activation. A kinetic study using a plasmin-resistant mutant pro-urokinase (Ala-158-rpro-UK). BioChemistry 31:6311–6317CrossRefPubMed Liu J, Gurewich V (1992) Fragment E-2 from fibrin substantially enhances pro-urokinase-induced glu-plasminogen activation. A kinetic study using a plasmin-resistant mutant pro-urokinase (Ala-158-rpro-UK). BioChemistry 31:6311–6317CrossRefPubMed
4.
go back to reference Liu J, Gurewich V (1991) A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. J Clin Invest 88:2012–2017CrossRefPubMedPubMedCentral Liu J, Gurewich V (1991) A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. J Clin Invest 88:2012–2017CrossRefPubMedPubMedCentral
5.
go back to reference Petersen LC (1997) Kinetics of reciprocal pro-urokinase/plasminogen activation. Stimulation by a template formed by the urokinase receptor bound to poly (d-lysine). Eur J Biochem 245:316–323CrossRefPubMed Petersen LC (1997) Kinetics of reciprocal pro-urokinase/plasminogen activation. Stimulation by a template formed by the urokinase receptor bound to poly (d-lysine). Eur J Biochem 245:316–323CrossRefPubMed
6.
go back to reference Pannell R, Black J, Gurewich V (1988) The complementary modes of action of tissue plasminogen activator (t-PA) and pro-urokinase (pro-UK) by which their synergistic effect on clot lysis may be explained. J Clin Invest 81:853–859CrossRefPubMedPubMedCentral Pannell R, Black J, Gurewich V (1988) The complementary modes of action of tissue plasminogen activator (t-PA) and pro-urokinase (pro-UK) by which their synergistic effect on clot lysis may be explained. J Clin Invest 81:853–859CrossRefPubMedPubMedCentral
7.
go back to reference Gurewich V, Pannell R (1987) Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect. Thromb Haemost 57:372–378PubMed Gurewich V, Pannell R (1987) Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect. Thromb Haemost 57:372–378PubMed
8.
go back to reference Liu JN, Tang W, Sun ZY, Kung W, Pannell R, Sarmientos P, Gurewich V (1996) A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity. BioChemistry 35:14070–14076CrossRefPubMed Liu JN, Tang W, Sun ZY, Kung W, Pannell R, Sarmientos P, Gurewich V (1996) A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity. BioChemistry 35:14070–14076CrossRefPubMed
9.
go back to reference Liu JN, Liu JX, Liu B, Sun Z, Zuo JL, Zhang P, Zhang J, Chen Y, Gurewich V (2002) A prourokinase mutant which induces highly effective clot lysis without interfering with hemostasis. Circu Res 90:757–763CrossRef Liu JN, Liu JX, Liu B, Sun Z, Zuo JL, Zhang P, Zhang J, Chen Y, Gurewich V (2002) A prourokinase mutant which induces highly effective clot lysis without interfering with hemostasis. Circu Res 90:757–763CrossRef
10.
go back to reference Pannell R, Li S, Gurewich V (2015) Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK. PLoS ONE 10:1–15CrossRef Pannell R, Li S, Gurewich V (2015) Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK. PLoS ONE 10:1–15CrossRef
11.
go back to reference Dmitry V, Sakharov J, Nagelkerke F, Dingeman C, Rijken DC (1996) Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. J Biol Chem 271:2133–2138CrossRef Dmitry V, Sakharov J, Nagelkerke F, Dingeman C, Rijken DC (1996) Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. J Biol Chem 271:2133–2138CrossRef
12.
go back to reference Suenson E, Lützen O, Thorsen S (1984) Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem 140:513–522CrossRefPubMed Suenson E, Lützen O, Thorsen S (1984) Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem 140:513–522CrossRefPubMed
13.
go back to reference Harpel PC, Chang TS, Verderber E (1985) Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I. J Biol Chem 260(7):4432 (abstr)PubMed Harpel PC, Chang TS, Verderber E (1985) Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I. J Biol Chem 260(7):4432 (abstr)PubMed
14.
go back to reference Gurewich V (2016) Therapeutic fibrinolysis. How efficacy and safety can be improved. J Am Coll Cardiol 68:2099–2106CrossRefPubMed Gurewich V (2016) Therapeutic fibrinolysis. How efficacy and safety can be improved. J Am Coll Cardiol 68:2099–2106CrossRefPubMed
15.
go back to reference Liu J, Pannell R, Gurewich V (1992) A transitional state of pro-urokinase which has a higher catalytic efficiency against glu-plasminogen than urokinase. J Biol Chem 267:15289–15292PubMed Liu J, Pannell R, Gurewich V (1992) A transitional state of pro-urokinase which has a higher catalytic efficiency against glu-plasminogen than urokinase. J Biol Chem 267:15289–15292PubMed
16.
go back to reference Baglin TP, Landown R, Frasson R, Huntington JA (2016) Discovery and characterization of an antibody directed against exosite 1 of thrombin. J Thrommb Haemos 14:137–142CrossRef Baglin TP, Landown R, Frasson R, Huntington JA (2016) Discovery and characterization of an antibody directed against exosite 1 of thrombin. J Thrommb Haemos 14:137–142CrossRef
17.
go back to reference Bugge TH, Flick MJ, Danton MJS, Daugherty CC, Rømer J, Danø K, Carmeliet P, Collen D, Degen JL (1996) Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 93:5899–5904CrossRefPubMedPubMedCentral Bugge TH, Flick MJ, Danton MJS, Daugherty CC, Rømer J, Danø K, Carmeliet P, Collen D, Degen JL (1996) Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 93:5899–5904CrossRefPubMedPubMedCentral
18.
go back to reference Singh I, Burnand KG, Collins M, Luttun A, Collen D, Boelhouwer B, Smith A (2003) Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation 107:869–875CrossRefPubMed Singh I, Burnand KG, Collins M, Luttun A, Collen D, Boelhouwer B, Smith A (2003) Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation 107:869–875CrossRefPubMed
19.
go back to reference Pannell R, Gurewich V (1992) A comparison of the rates of clot lysis in a plasma milieu induced by tissue plasminogen activator (t-PA) and rec-prourokinase: evidence that t-PA has a more restricted mode of action. Fibrinolysis 6:1–5CrossRef Pannell R, Gurewich V (1992) A comparison of the rates of clot lysis in a plasma milieu induced by tissue plasminogen activator (t-PA) and rec-prourokinase: evidence that t-PA has a more restricted mode of action. Fibrinolysis 6:1–5CrossRef
20.
go back to reference Vaughan DE, Vautloutle E, Collen D (1990) Urokinase binds to platelets through a specific saturable, low affinity mechanism. Fibrinolysis 4:141CrossRef Vaughan DE, Vautloutle E, Collen D (1990) Urokinase binds to platelets through a specific saturable, low affinity mechanism. Fibrinolysis 4:141CrossRef
21.
go back to reference Gurewich V, Johnstone MT, Pannell R (1995) The selective uptake of high molecular weight urokinase-type plasminogen activator by human platelets. Fibrinolysis 9:188–195CrossRef Gurewich V, Johnstone MT, Pannell R (1995) The selective uptake of high molecular weight urokinase-type plasminogen activator by human platelets. Fibrinolysis 9:188–195CrossRef
22.
go back to reference Grau E, Moroz LA (1989) Fibrinolytic activity of normal human blood monocytes. Thromb Res 53:145–162CrossRefPubMed Grau E, Moroz LA (1989) Fibrinolytic activity of normal human blood monocytes. Thromb Res 53:145–162CrossRefPubMed
23.
go back to reference Gurewich V, Emmons F, Pannell R (1988) Spontaneous clot lysis in whole human plasma by endogenous tissue type and urokinase type plasminogen activators: demonstration of a promoting effect by tPA and by platelets on urokinase. Fibrinolysis 2:143–149CrossRef Gurewich V, Emmons F, Pannell R (1988) Spontaneous clot lysis in whole human plasma by endogenous tissue type and urokinase type plasminogen activators: demonstration of a promoting effect by tPA and by platelets on urokinase. Fibrinolysis 2:143–149CrossRef
24.
go back to reference Zarich SW, Kowalchuk GJ, Weaver WD, Loscalzo J, Sassower M, Manzo K, Byrnes C, Muller JE, Gurewich V for the PATENT Study Group (1995) Sequential combination thrombolytic therapy for acute myocardial infarction: results of the pro-urokinase and t-PA enhancement of thrombolysis (PATENT) trial. J Am Coll Cardio 26:374–379CrossRef Zarich SW, Kowalchuk GJ, Weaver WD, Loscalzo J, Sassower M, Manzo K, Byrnes C, Muller JE, Gurewich V for the PATENT Study Group (1995) Sequential combination thrombolytic therapy for acute myocardial infarction: results of the pro-urokinase and t-PA enhancement of thrombolysis (PATENT) trial. J Am Coll Cardio 26:374–379CrossRef
25.
go back to reference Ross AM for the GUSTO Angiographic Investigators (1993) The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329:1615–1622CrossRef Ross AM for the GUSTO Angiographic Investigators (1993) The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329:1615–1622CrossRef
Metadata
Title
Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination
Authors
R. Pannell
S. Li
V. Gurewich
Publication date
01-08-2017
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2017
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-017-1514-0

Other articles of this Issue 2/2017

Journal of Thrombosis and Thrombolysis 2/2017 Go to the issue